Research Projects Available
Dphil in cardiovascular science
DPhil in medical sciences opportunities will appear below:
MSc by Research in medical sciences opportunities will appear below:
Colleges
Websites
-
Sky news
Findings from the C-MORE - multiorgan MRI Study
-
BBC news
Findings from the C-MORE - multiorgan MRI Study
-
BBC world radio
Betty Raman presenting findings from the C-MORE study (8:20)
Betty Raman
MBBS DPhil FESC FRACP
Associate Professor of Cardiovascular Medicine
- NIHR South Central RRDN Cardiology Specialty Lead
- Hon. Consultant Cardiologist (Loc)
- Oxford Programme Director of BHF Doctoral Training Programme on Technology, Data and AI (Imperial-Oxford DTP)
- Wellcome Career Development Award Fellow
- RDM Cardiovascular Medicine EDI Champion
Prof Betty Raman is a senior honorary consultant cardiologist specialising in advanced cardiovascular imaging (CMR and cardiac CT) and inherited and cardiomyopathic heart disease. She leads a translational research programme in monogenic (e.g., HCM, DCM etc) and polygenic cardiac (hypertensive heart diseases, cardiometabolic etc.) diseases that bridge mechanistic discovery, clinical application, and innovation in drug development.
After completing her specialist cardiology training in Australia (FRACP), she joined the University of Oxford in 2015 to pursue a DPhil in hypertrophic cardiomyopathy, the leading cause of sudden cardiac death in young adults and athletes. Her doctoral work led to the development of a novel oxygen sensitive magnetic resonance method that detects myocardial hypoxia non-invasively and holds promise as an early biomarker of disease activity. This pioneering work has been recognised internationally through awards from the ESC, AHA, BSCMR, SCMR, and BCS.
Building on this foundation, she was awarded a British Heart Foundation Transition Fellowship (2020) and subsequently a Wellcome Career Development Award (2024) to advance a multidisciplinary research programme integrating imaging, genetics, energetics, and computational modelling. Her goal is to identify and validate early markers of disease progression in hypertrophic (e.g., HCM) and related cardiomyopathies, enabling more precise risk prediction and supporting evaluation of emerging therapies.
During the COVID 19 pandemic, she led the C-MORE study, a large multicentre initiative that combined MRI, cardiopulmonary exercise testing, and cognitive assessments to characterise the long term multi organ consequences of COVID 19. This work helped shape understanding of post-viral cardiovascular and systemic recovery.
Her current research focuses on:
Early stage disease detection and monitoring in cardiomyopathies using next generation CMR including BOLD, DTI, spectroscopy, and radiomics.
Mechanistic biomarkers to support early phase and adaptive clinical trials.
Cross organ interactions in cardiometabolic disease, integrating heart, brain, liver, and renal imaging.
As a senior academic leader, she collaborates widely across academia, the NHS, and industry to translate advanced imaging into clinical and commercial impact. She actively welcomes scientific collaborators, students, and industrial partners interested in biomarker discovery, imaging enabled trial design, and AI based modelling for cardiovascular disease.
